TCF7L2

Across TCGA pan-cancer cohorts, TCF7L2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TCF7L2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher TCF7L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCF7L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CHOL, LUAD, and LGG are the cancer types where TCF7L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LGG	OS	Median	All	0.255	0.799	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.940	0.625	.024	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	DFS	Median	III,IV	0.153	0.547	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TCF7L2–CHOL (OS)

Open the CHOL breakdown →